Dose response effects of lisdexamfetamine dimesylate treatment in adults with ADHD: an exploratory study.

Published

Journal Article

OBJECTIVE: To explore dose-response effects of lisdexamfetamine dimesylate (LDX) treatment for ADHD. METHOD: This was a 4-week, randomized, double-blinded, placebo-controlled, parallel-group, forced-dose titration study in adult participants, aged 18 to 55 years, meeting Diagnostic and Statistical Manual of Mental Disorders (4th ed., text rev.) criteria for ADHD. RESULTS: Nearly all participants assigned to an LDX dose achieved their assigned dose with the exception of about 4% of participants assigned to the 50 mg or 14% assigned to the 70 mg doses. Higher doses of LDX led to greater improvements in ADHD-rating scale scores, independent of prior pharmacotherapy. This was evident for both inattentive and hyperactive-impulsive symptoms. The authors found some evidence for an interaction between LDX dose and baseline severity of ADHD symptoms. CONCLUSION: For LDX doses between 30 and 70 mg/d, the dose-response efficacy effect for LDX is not affected by prior pharmacotherapy, but patients with a greater severity of illness may benefit more from higher doses, especially for hyperactive-impulsive symptoms. The results do not provide information about doses above 70 mg/d, which is the maximum approved dose of LDX and the highest dose studied in ADHD clinical trials.

Full Text

Duke Authors

Cited Authors

  • Faraone, SV; Spencer, TJ; Kollins, SH; Glatt, SJ; Goodman, D

Published Date

  • February 2012

Published In

Volume / Issue

  • 16 / 2

Start / End Page

  • 118 - 127

PubMed ID

  • 21527575

Pubmed Central ID

  • 21527575

Electronic International Standard Serial Number (EISSN)

  • 1557-1246

Digital Object Identifier (DOI)

  • 10.1177/1087054711403716

Language

  • eng

Conference Location

  • United States